



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

HOUSTON  
WASHINGTON, D.C.  
AUSTIN  
SAN ANTONIO  
DALLAS  
NEW YORK  
LOS ANGELES  
MINNEAPOLIS  
LONDON  
HONG KONG

TELEPHONE: 512/474-5201  
FAX: 512/536-4598

WRITER'S INTERNET ADDRESS:  
TSCHULTZ@FULBRIGHT.COM

WRITER'S DIRECT DIAL NUMBER:  
512/536-3020

RECEIVED

JUN 08 2001

June 4, 2001

TECH CENTER 1600/2900

FILE: ARCD:272USC1

10100267

CERTIFICATE OF MAILING  
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

4 June 2001  
Date

Jerisa G. Schultz  
Signature

Commissioner for Patents  
Washington, DC 20231

RE: SN 09/754,106 "MUTATIONS IN THE DIABETES SUSCEPTIBILITY GENES  
HEPATOCTE NUCLEAR FACTOR (HNF) 1 ALPHA ( $\alpha$ ), HNF-1 $\beta$  AND HNF-4 $\alpha$ "  
- Graeme I. Bell, et al.

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) Statement as Required Under 37 C.F.R. §1.825(a) and (b) and Statement as Requested Under 37 C.F.R. §1.821(g);
- (2) Paper copy of the Sequence Listing;
- (3) Computer readable form of Sequence Listing; and
- (4) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10100267/01964.

Commissioner for Patents  
June 4, 2001  
Page 2



RECEIVED

JUN 08 2001

TECH CENTER 1600/2900

Respectfully submitted,

*Teresa J. Schultz*

Teresa J. Schultz  
Reg. No. 40,526

TJS/jmh  
Encl.: